Table 1.
Cell lines and culture conditions used in this study
| Cell line | Gender | Cell type | Tissue of origin | Obtained from | Culture conditions |
|---|---|---|---|---|---|
| A549 | M | Alveolar basal epithelial (adherent) | Lung adenocarcinoma |
ATCC CCL-185 |
ATCC F12K (ATCC, P/N 30-2004) +10% FCS (AMIMED, P/N 2-01F36-I). |
| H1437 | M | Epithelial/glandular (adherent) | Lung adenocarcinoma, derived from metastatic site: pleural effusion |
ATCC CRL-5872 |
RPMI (Invitrogen, P/N A1049101) +10% FBS (ATCC, P/N SCRR-30-2020) |
| HCT116 | M | Epithelium-like (adherent) | Colon carcinoma |
ATCC CCL-247 |
ATCC McCoy's 5A (ATCC, P/N 30-2007) + 10% FCS (AMIMED, P/N 2-01F36-I) |
| HEK293 | F | Epithelial (adherent) | Transformed cell line, derived from embryonic kidney | ATCC, P/N CRL-1573 | ATCC EMEM (ATCC, P/N 30-2003) +10% FCS (AMIMED, P/N 2-01F36-I) |
| IMR90 | F | Fibroblast (adherent) | Fetal lung |
ATCC CRL-186 |
ATCC EMEM (ATCC, P/N 30-2003) 10% FCS (AMIMED, P/N 2-01F36-I) |
| Jurkat | M | T cell (suspension) | Childhood T acute lymphoblastic leukemia | ATCC, P/N TIB-152 | RPMI (Invitrogen, P/N 61870-044) + 10% FCS (AMIMED, P/N 2-01F36-I) |
| K562 | F | Undifferentiated, lymphoblast with granulocyte/erythrocyte/monocyte characteristics (suspension) | Chronic myelogenous leukemia, BCR-ABL1 positive | ATCC, P/N CRL-1573 | RPMI (Invitrogen, P/N 61870-044) + 10% FCS (AMIMED, P/N 2-01F36-I). |
| Ramos | M | B cell (suspension) | Burkitt’s lymphoma | ATCC, P/N CRL-1596 |
Batch 3: RPMI (Invitrogen, P/N A1049101) +10% FBS (ATCC, P/N SCRR-30-2020) Batch 4: RPMI (Invitrogen, P/N 61870-044) + 10% FCS (AMIMED, P/N 2-01F36-I) |